Waltham, Mass., May 15, 2023 – Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will participate in four upcoming scientific conferences. The presentations will describe the company’s new technologies and approaches to using AI and machine learning in the drug discovery process for RNA-targeted small molecules.
Details of the Arrakis presentations are as follows:
Bio-IT World Conference & Expo, Boston, MA
Presentation Title: RNA-Binding Chemotypes: A Case Study in Data Exploration and Machine Learning
Date: Wednesday, May 17
Time: 3:40 p.m. ET
Presenter: Kimberly Robasky, PhD, Associate Director, Data Sciences
4th RNA Editing Summit, Boston, MA
Presentation Title: Discovering Targetable mRNA Structures in the Transcriptome
Date: Thursday, July 13
Presenter: David Mauger, PhD, Director, Data Sciences
2023 Computer Aided Drug Design Gordon Research Conference, Mount Snow, VT
Presentation Title: Structure-based Approaches to Explore RNA Chemical Space
Date: Monday, July 17
Presenter: Aaron Frank, PhD, Director, Computational Chemistry
National Consortium for Data Science DataBytes Webinar
Presentation Title: AI in Target Identification and Drug Discovery: Transforming the Future of Medicine
Date: Tuesday, August 22
Presenter: Kimberly Robasky, PhD, Associate Director, Data Sciences
About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.